Compare Medpace Holdings Inc (MEDP) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: Medpace Holdings Inc is far larger — about 11.6× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is more actively traded (323,568 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| MEDP | QQQE | |
|---|---|---|
Market Cap | $16.82B | $1.45B |
Volume | 223,093 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $124.69 |
52-Week Low | $393.42 | $96.06 |
Typical Hold Time | 14 Days | 48 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
